Anaplastic lymphoma kinase (ALK) gene rearrangements have been identified as potent
oncogenic drivers in several malignancies, including non-small cell lung cancer (NSCLC) …

Anaplastic lymphoma kinase (ALK) is a validated molecular target in several ALK-
rearranged malignancies, particularly in non-small-cell lung cancer (NSCLC), which has …

Anaplastic lymphoma kinase (ALK) is a validated molecular target in several ALK-
rearranged malignancies, including non–small cell lung cancer. However, the clinical …

Anaplastic lymphoma kinase (ALK) rearrangement is one of the oncogenes in non-small cell
lung cancer (NSCLC) identified in 2007. The PROFILE trials demonstrated that patients with …

Anaplastic lymphoma kinase (ALK) gene encoding the receptor tyrosine kinase ALK is
expressed as a fusion gene in a variety of carcinomas. The expression of ALK is nearly …

The oncogenic function of gene translocations involving the anaplastic lymphoma kinase
(ALK) was first reported in rare subtypes of non-Hodgkin's lymphoma almost two decades …

The anaplastic lymphoma tyrosine kinase (ALK) gene was first described as a driver
mutation in anaplastic non-Hodgkin's lymphoma. Dysregulated ALK expression is now an …

The anaplastic lymphoma kinase (ALK) gene plays an important physiologic role in the
development of the brain and can be oncogenically altered in several malignancies …

Background Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have
shown efficacy in the treatment of ALK-rearranged non–small-cell lung cancer (NSCLC), but …

Simple Summary Lung cancer is a devastating disease, with non-small cell lung cancer
(NSCLC) being the most common subtype. With the development of novel targeted …